PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mycophenolate→

Mycophenolate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
24280-93-1
Molecular formula
C17H19O6-
Molecular weight
319.3 g/mol
Drug class
Immunosuppressant antimetabolitemycophenolic acid active moiety
Mechanism of action
Inhibits inosine monophosphate dehydrogenase (IMPDH), preferentially suppressing de-novo guanosine nucleotide synthesis in activated T and B lymphocytes and reducing lymphocyte proliferation. Specific prodrug salts/forms such as mycophenolate mofetil and mycophenolate sodium are separate dosage forms that deliver mycophenolic acid.
Indications / reported uses
  • Used in combination immunosuppressive regimens to prevent allograft rejection after kidney, heart or liver transplantation, depending on the particular mycophenolic acid formulation and jurisdiction
  • Off-label use in selected autoimmune disorders is not a universal product-authorised indication

Sources: US DailyMed — Mycophenolate mofetil labels · NLM MeSH — Mycophenolic acid · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Mycophenolate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mycophenolate Permitted Daily Exposure (PDE) report (the Mycophenolate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mycophenolate Occupational Exposure Limit (OEL) report (the Mycophenolate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.